β-Galactosidase Deficiency in Colombia: Report of 20 Patients Detected Using Dried Blood Spot Samples
Autor: | Isidro Arevalo, Adis Ayala, Natalia Pacheco, Lina Manuela Jay Garcia, Monica España, Alfredo Uribe |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2015 |
Předmět: |
chemistry.chemical_classification
Pathology medicine.medical_specialty GM1 gangliosidosis Catabolism business.industry leukocytes Endocrinology Diabetes and Metabolism GM1 Gangliosidosis β-galactosidase Molecular biology Sphingolipid dried blood spot Dried blood spot carbohydrates (lipids) Enzyme chemistry Morquio B Pediatrics Perinatology and Child Health Medicine lipids (amino acids peptides and proteins) business Genetics (clinical) |
Zdroj: | Journal of Inborn Errors of Metabolism and Screening v.3 2015 Journal of Inborn Errors of Metabolism and Screening Instituto Genética para Todos (IGPT) instacron:IGPT |
Popis: | β-Galactosidase (BGal) is the first enzyme involved in the catabolism of sphingolipids. Two pathologies have been directly associated with its deficiency: GM1 gangliosidosis and Morquio B. Morquio B is among the rarest types of mucopolysaccharidosis (MPS). We aim to document the β-galactosidase deficiency in Colombia. We evaluated leukocytes from 1492 healthy Colombian individuals and 923 patients, referred between 2005 and August 2014. Dried blood spot (DBS) samples from the same number of patients were evaluated. β-Galactosidase was measured with 4-methylumbelliferyl-β-d-galactoside. As a control enzyme, the total hexosaminidase activity was also evaluated. We identified 14 patients with GM1 gangliosidosis, 5 patients with Morquio B, and 1 patient with I-cell disease. We could establish a reference value for Bgal in Colombian leukocyte samples. GM1 gangliosidosis is the main pathology associated with a direct deficiency of BGal. The high number of patients found with MPS IVB indicates that there are patients who could be misdiagnosed due to an unawareness of the disease. |
Databáze: | OpenAIRE |
Externí odkaz: |